1
|
Murugesan K, Necchi A, Burn TC, Gjoerup O, Greenstein R, Krook M, López JA, Montesion M, Nimeiri H, Parikh AR, Roychowdhury S, Schwemmers S, Silverman IM, Vogel A. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations. ESMO Open 2022; 7:100641. [PMID: 36462464 PMCID: PMC9832751 DOI: 10.1016/j.esmoop.2022.100641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Revised: 10/24/2022] [Accepted: 10/25/2022] [Indexed: 12/05/2022] Open
Abstract
BACKGROUND Selective tyrosine kinase inhibitors targeting fibroblast growth factor receptor (FGFR) 1-4 genomic alterations are in development or have been approved for FGFR-altered cancers (e.g. bladder cancer and advanced intrahepatic cholangiocarcinoma). Understanding FGFR inhibitor-resistance mechanisms is increasingly relevant; we surveyed the pan-tumor landscape of FGFR1-4 genomic alterations [short variants (SVs), gene rearrangements (REs), and copy number alterations (CNAs)], including their association with tumor mutational burden (TMB) and the genomic comutational landscape. PATIENTS AND METHODS Comprehensive genomic profiling of 355 813 solid tumor clinical cases was performed using the FoundationOne and FoundationOne CDx assays (Foundation Medicine, Inc.) to identify genomic alterations in >300 cancer-associated genes and TMB (determined on ≤1.1 megabases of sequenced DNA). RESULTS FGFR1-4 SVs and REs occurred in 9603/355 813 (2.7%), and CNAs in 15 078/355 813 (4.2%) samples. Most common FGFR alterations for bladder cancer, intrahepatic cholangiocarcinoma, and glioma were FGFR3 SVs (1051/7739, 13.6%), FGFR2 REs (618/6641, 9.3%), and FGFR1 SVs (239/11 550, 2.1%), respectively. We found several, potentially clinically relevant, tumor-specific associations between FGFR1-4 genomic alterations and other genomic markers. FGFR3 SV-altered bladder cancers and FGFR1 SV-altered gliomas were significantly less likely to be TMB-high versus unaltered samples. FGFR3 SVs in bladder cancer significantly co-occurred with TERT and CDKN2A/B alterations; TP53 and RB1 alterations were mutually exclusive. In intrahepatic cholangiocarcinoma, FGFR2 REs significantly co-occurred with BAP1 alterations, whereas KRAS, TP53, IDH1, and ARID1A alterations were mutually exclusive. FGFR1 SVs in gliomas significantly co-occurred with H3-3A and PTPN11 alterations, but were mutually exclusive with TERT, EGFR, TP53, and CDKN2A/B alterations. CONCLUSIONS Overall, our hypothesis-generating findings may help to stratify patients in clinical trials and guide optimal targeted therapy in those with FGFR alterations.
Collapse
Affiliation(s)
- K Murugesan
- Cancer Genomics Research, Foundation Medicine, Inc., Cambridge, USA
| | - A Necchi
- Genitourinary Medical Oncology, Vita-Salute San Raffaele University, Milan; Genitourinary Medical Oncology, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy
| | - T C Burn
- Translational and Data Sciences, Incyte Corporation, Wilmington
| | - O Gjoerup
- Scientific and Medical Publications, Foundation Medicine, Inc., Cambridge, USA
| | - R Greenstein
- Cancer Genomics Research, Foundation Medicine, Inc., Cambridge, USA
| | - M Krook
- Research Scientist, Ohio State University, Columbus, USA
| | - J A López
- Integrated Healthcare Solutions, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - M Montesion
- Cancer Genomics Research, Foundation Medicine, Inc., Cambridge, USA
| | - H Nimeiri
- Global Clinical Development Lead Oncology, Foundation Medicine, Inc., Cambridge, USA
| | - A R Parikh
- Oncology (Medical/Hematology), Jefferson Health, Philadelphia, USA
| | | | - S Schwemmers
- Integrated HealthCare Solutions PDMA (Oncology), F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - I M Silverman
- Clinical Bioinformatics, Incyte Corporation, Wilmington
| | - A Vogel
- Clinic for Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, Hannover, Germany.
| |
Collapse
|
2
|
Necchi A, Murugesan K, Burn T, Gjoerup O, Greenstein R, López J, Montesion M, Nimeiri H, Parikh A, Roychowdhury S, Schwemmers S, Silverman I, Vogel A. 100P Co-mutational landscape of key fibroblast growth factor receptor (FGFR) alterations in intra-hepatic cholangiocarcinoma (iCCA), bladder cancer (BC) and glioma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
3
|
Tejpar S, Tukachinsky H, Zhang L, Schrock A, Decker B, Pavlick D, Venstrom J, Nimeiri H, Oxnard G. 457P Circulating tumor DNA (ctDNA) from patients (pts) with advanced colorectal cancer (CRC) is enriched for EGFR extracellular domain (ECD) mutations. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
4
|
Hann C, Burns T, Dowlati A, Morgensztern D, Koch M, Chang YW, Komarnitsky P, Ludwig C, Nimeiri H, Camidge D. A phase I study evaluating rovalpituzumab tesirine (ROVA-T) in frontline treatment of patients (pts) with extensive stage small cell lung cancer (ES-SCLC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz264.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Morris V, Ciombor K, Salem M, Nimeiri H, Iqbal S, Singh P, Polite B, Deming D, Chan E, Wade J, Bekaii-Saab T, Wolff R, Eng C. O-022 A multi-institutional phase 2 study of single agent nivolumab in previously treated metastatic squamous cell carcinoma of the anal canal (SCCA). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw198.22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Landry J, Feng Y, Cohen S, Staley C, Whittington R, Sigurdson E, Nimeiri H, Verma U, Prabhu R, Benson A. Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: ECOG 3204. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|